Hawaii Pacific Neuroscience

The trials here

What the 33 trials at this site are about, from their registry records.

Conditions

• Epilepsy12 trials
• Alzheimer disease8 trials
• Parkinson disease4 trials
• Lewy body dementia2 trials
• Multiple sclerosis2 trials
• Myasthenia gravis2 trials
• ALS (motor neurone disease)1 trial
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 trial
• Essential tremor1 trial
• Idiopathic pulmonary fibrosis1 trial
• Multiple system atrophy1 trial

Phase

• Phase 316 trials
• Phase 210 trials
• Phase 1/22 trials
• Phase 11 trial
• Phase 2/31 trial
• Phase 41 trial

Status

• Active, not recruiting11 trials
• Completed9 trials
• Recruiting9 trials
• Enrolling by invitation2 trials
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Hoffmann-La Roche4 trials
• Xenon Pharmaceuticals Inc.3 trials
• ACADIA Pharmaceuticals Inc.2 trials
• Biogen2 trials
• Biohaven Therapeutics Ltd.2 trials
• and 18 more

Running trials

• Recruiting

  A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

  NCT07717411· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

  NCT07594119· Phase 3· Rapport Therapeutics Inc.· Source

  Contact: Rapport Medical

• Active, not recruiting

  A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

  NCT07501702· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07095465· Phase 3· ACADIA Pharmaceuticals Inc.· Source

  Contact: Kristin Kidd

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07029581· Phase 2· ACADIA Pharmaceuticals Inc.· Source

  Contact: Kristin Kidd

• Recruiting

  RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

  NCT07002034· Phase 2· Reunion Neuroscience Inc· Source

  Contact: Peter Nguyen

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care

  NCT06538064· Takeda· Source

  Contact: Kore Liow (principal investigator)

• Recruiting

  A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

  NCT06909214· Phase 4· argenx· Source

  Contact: Natalia Gonzalez Caldito, MD

• Active, not recruiting

  A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

  NCT06709014· Phase 3· Annovis Bio Inc.· Source

• Active, not recruiting

  Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

  NCT06700343· Phase 3· Amgen· Source

• Active, not recruiting

  Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation

  NCT07084311· Phase 1/2· n-Lorem Foundation· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06132893· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

  NCT05696717· Phase 3· Theravance Biopharma· Source

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· Phase 2· Biogen· Source

• Active, not recruiting

  Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

  NCT04006210· Phase 3· NeuroDerm Ltd.· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Eisai Inc.· Source

• Active, not recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

  NCT03796962· Phase 2· Xenon Pharmaceuticals Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy3 recruiting
• Alzheimer disease2 recruiting
• Lewy body dementia2 recruiting
• Parkinson disease2 recruiting
• ALS (motor neurone disease)1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting

Closed trials

• Completed

  A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

  NCT06538116· Phase 2· Eli Lilly and Company· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

  NCT05626634· Phase 2· Longboard Pharmaceuticals· Source

• Withdrawn

  ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

  NCT05481905· Phase 2· Engrail Therapeutics INC· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

  NCT05364021· Phase 1/2· Longboard Pharmaceuticals· Source

• Completed

  A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

  NCT05122650· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  Lu AF28996 in Participants With Parkinson's Disease (PD)

  NCT04291859· Phase 1· H. Lundbeck A/S· Source

• Completed

  Cenobamate Open-Label Extension Study for YKP3089C025

  NCT03961568· Phase 3· SK Life Science, Inc.· Source

• Completed

  Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

  NCT03678753· Phase 3· SK Life Science, Inc.· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· LivaNova· Source